Table 3.

First-line chemotherapy regimens for 109 patients with metastatic nonmucinous appendiceal adenocarcinoma

Regimen	Number of patients (%)
Oxaliplatin-based	60 (55)
FOLFOX or XELOX	18 (17)
FOLFOX or XELOX + bevacizumab	39 (36)
FOLFOX or XELOX + cetuximab	2 (2)
EOX	1 (1)
Irinotecan-based	29 (27)
FOLFIRI	5 (5)
Irinotecan alone	3 (3)
FOLFIRI + cetuximab	2 (2)
FOLFIRI + bevacizumab	12 (11)
FOLFIRI + bevacizumab + cetuximab	1 (1)
FOLFIRI + thalidomide	1 (1)
Irinotecan + cisplatin	4 (4)
Irinotecan + cetuximab	1 (1)
Fluoropyrimidine alone	13 (12)
Other	7 (6)
Irinotecan + oxaliplatin + bevacizumab	1 (1)
Carboplatin + paclitaxel	1 (1)
5-FU or capecitabine + cisplatin	4 (4)
5-FU + interferon	1 (1)

Abbreviations: 5-FU 5-fluorouracil, FOLFOX 5-FU + oxaliplatin, XELOX capecitabine (Xeloda) + oxaliplatin, EOX epirubicin + oxaliplatin, FOLFIRI 5-FU + irinotecan